Ratings NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
21.99 ^USD	-0.81%		+33.52%	+47.29%

May. 02	NovoCure Shares Steady After Reporting Narrower Q1 Loss, Higher Revenue	MT
May. 02	BioPharma Credit Enters $400 Million Loan Agreement with Novocure Luxembourg	MT

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

Sales forecast by analysts have been recently revised upwards.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
One of the major weak points of the company is its financial situation.
The company's enterprise value to sales, at 3.91 times its current sales, is high.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
NOVOCURE LIMITED	+47.29%	2.37B	C-
SHOCKWAVE MEDICAL, INC.	+73.24%	12.39B	B-
PENUMBRA, INC.	-19.09%	7.89B	C+
MASIMO CORPORATION	+5.88%	6.59B	C-
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+13.24%	5.43B	D+
APT MEDICAL INC.	+38.48%	4.96B	-
GETINGE AB	-17.30%	4.72B	B
ASAHI INTECC CO., LTD.	-19.78%	4.02B	B-
INARI MEDICAL, INC.	-29.53%	2.66B	C
SKAN GROUP AG	-2.10%	1.96B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes